Single-Domain Antibody Generation Services Tender, USA - 86964275

Procurement Summary

Country : USA

Summary : Single-Domain Antibody Generation Services

Deadline : 10 Aug 2023

Other Information

Notice Type : Tender

TOT Ref.No.: 86964275

Document Ref. No. : NIHNEI080823

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Name :Login to see tender_details

Address : Login to see tender_details

Email : Login to see tender_details

Login to see details

Tender Details

Description

The National Institutes of Health (NIH) intends to award a Firm-Fixed-Price purchase order to ProSci, Llc. for custom services order to develop recombinant single-domain antibodies (sdAbs) by llama immunization.

In accordance with FAR Part 6.302-1, the Contractor is the only known responsible source who can provide the specific continued single-domain antibody generation services per SOW below. This notice is not a request for competitive quotes. However, any party that believes it can provide the services as stated herein may submit a written capability statement that clearly supports and demonstrates their ability to satisfy the requirement. A determination by the Government to compete this proposed award based upon responses to this notice is solely within the discretion of the Government. It is anticipated that an award will be issued approximately five (5) days after the date of this notice unless the Government determines that another organization has the capability to meet this requirement. Please email responses to Sharmaine.fagan@nih.gov no later than 08:00 a.m. EST on Thursday, August 10, 2023.



SCOPE:

The primary objective of this custom services order through ProSci, Llc., is to develop recombinant single-domain antibodies (sdAbs) by llama immunization. sdAbs are very compact antibodies that are used for a variety of basic research and translational procedures. sdAbs are isolated from camelid (such as llama) heavy-chain-only antibodies and are comprised of only the variable domain. As such, they lack light chains, are smaller and more stable compared to conventional antibodies, yet possess fully functional antigen-binding capability. Due to their size (approximately 15 kDa, one-tenth the size of conventional antibodies) and their longer CDR3 region, a single domain antibody can reach otherwise inaccessible epitopes. Phage display technology is used to develop functional single domain antibodies. We wish to develop sdAbs ag...
Active Contract Opportunity
Notice ID : NIHNEI080823
Related Notice
Department/Ind. Agency : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier : NATIONAL INSTITUTES OF HEALTH
Office : NATIONAL INSTITUTES OF HEALTH OLAO
General Information
Contract Opportunity Type: Special Notice (Original)
All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
Original Published Date: Aug 08, 2023 04:14 pm EDT
Original Response Date: Aug 10, 2023 08:00 am EDT
Inactive Policy: 15 days after response date
Original Inactive Date: Aug 25, 2023
Initiative: None

Classification
Original Set Aside:
Product Service Code: B504 - SPECIAL STUDIES/ANALYSIS- CHEMICAL/BIOLOGICAL
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance: Rockville, MD 20852 USA

Documents

 Tender Notice